SI3218720T1 - Biomarkerji za napredovanje bolezni pri melanomu - Google Patents

Biomarkerji za napredovanje bolezni pri melanomu

Info

Publication number
SI3218720T1
SI3218720T1 SI201530554T SI201530554T SI3218720T1 SI 3218720 T1 SI3218720 T1 SI 3218720T1 SI 201530554 T SI201530554 T SI 201530554T SI 201530554 T SI201530554 T SI 201530554T SI 3218720 T1 SI3218720 T1 SI 3218720T1
Authority
SI
Slovenia
Prior art keywords
biomarkers
melanoma
disease progression
progression
disease
Prior art date
Application number
SI201530554T
Other languages
English (en)
Inventor
Marie Labus
Penny Lovat
Robert Ellis
Original Assignee
Amlo Biosciences Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amlo Biosciences Limited filed Critical Amlo Biosciences Limited
Publication of SI3218720T1 publication Critical patent/SI3218720T1/sl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/5743Specifically defined cancers of skin, e.g. melanoma
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/20Dermatological disorders
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/56Staging of a disease; Further complications associated with the disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7023(Hyper)proliferation
    • G01N2800/7028Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201530554T 2014-11-10 2015-11-05 Biomarkerji za napredovanje bolezni pri melanomu SI3218720T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1419976.4A GB201419976D0 (en) 2014-11-10 2014-11-10 Biomarkers for disease progression in melanoma
EP15794627.8A EP3218720B1 (en) 2014-11-10 2015-11-05 Biomarkers for disease progression in melanoma
PCT/GB2015/053347 WO2016075440A1 (en) 2014-11-10 2015-11-05 Biomarkers for disease progression in melanoma

Publications (1)

Publication Number Publication Date
SI3218720T1 true SI3218720T1 (sl) 2019-02-28

Family

ID=52118258

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201530554T SI3218720T1 (sl) 2014-11-10 2015-11-05 Biomarkerji za napredovanje bolezni pri melanomu

Country Status (14)

Country Link
US (2) US10634678B2 (sl)
EP (1) EP3218720B1 (sl)
JP (1) JP6808632B2 (sl)
CN (1) CN107003318B (sl)
AU (1) AU2015344858B2 (sl)
BR (1) BR112017006315B1 (sl)
CA (1) CA2963753C (sl)
DK (1) DK3218720T3 (sl)
ES (1) ES2705614T3 (sl)
GB (1) GB201419976D0 (sl)
MX (1) MX2017006075A (sl)
NZ (1) NZ729773A (sl)
SI (1) SI3218720T1 (sl)
WO (1) WO2016075440A1 (sl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201419976D0 (en) 2014-11-10 2014-12-24 Univ Newcastle Biomarkers for disease progression in melanoma
GB201818618D0 (en) 2018-11-15 2019-01-02 Amlo Biosciences Ltd Monoclonal antibodies against ambra-1
GB201818622D0 (en) 2018-11-15 2019-01-02 Amlo Biosciences Ltd Monoclonal antibodies against loricrin
GB201906297D0 (en) * 2019-05-03 2019-06-19 Amlo Biosciences Ltd Biomarkers for disease progression in squamous cell carcinoma
GB201911210D0 (en) * 2019-08-06 2019-09-18 Amlo Biosciences Ltd Clinical management of oropharyngeal squamous cell carcinoma
GB202214762D0 (en) 2022-10-07 2022-11-23 Amlo Biosciences Ltd Prognostic biomarker for melanoma

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020151487A1 (en) * 2000-08-31 2002-10-17 Loyola University Chicago Method and reagents for epithelial barrier formation and treatment of malignant and benign skin disorders by modulating the notch pathway
IL158969A0 (en) * 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
WO2004076621A2 (en) * 2003-02-27 2004-09-10 Yeda Research And Development Co. Ltd. Compositions of nucleic acids for treating and detecting influenza virus
US20050154020A1 (en) * 2004-01-14 2005-07-14 Synaptic Pharmaceutical Corporation 4-Aryl piperidines
US7615349B2 (en) * 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
AU2007299846B2 (en) * 2006-09-19 2014-11-20 Metabolon, Inc. Biomarkers for prostate cancer and methods using the same
ITRM20070351A1 (it) 2007-06-22 2008-12-23 Istituto Naz Per Le Malattie I Gene codificante la proteina ambra 1 avente attivita' regolatoria dell autofagia e dello sviluppo del sistema nervoso centrale
US20110268722A1 (en) 2010-04-22 2011-11-03 Siegelin Markus D Combination therapies with mitochondrial-targeted anti-tumor agents
US20120201750A1 (en) * 2010-09-20 2012-08-09 Bungwoo Ryu Serum biomarkers for melanoma metastasis
US20150166646A1 (en) 2012-06-15 2015-06-18 The Wistar Institute Of Anatomy And Biology Methods and Compositions for Treating or Diagnosing Melanoma
JP6281831B2 (ja) 2012-12-28 2018-02-21 国立大学法人北海道大学 神経変性疾患の制御因子
CN103642927B (zh) 2013-12-13 2015-04-15 青岛大学医学院附属医院 一种检测自噬信号通路的试剂、pcr检测方法及其应用
GB201419976D0 (en) 2014-11-10 2014-12-24 Univ Newcastle Biomarkers for disease progression in melanoma

Also Published As

Publication number Publication date
CN107003318A (zh) 2017-08-01
CN107003318B (zh) 2020-02-07
CA2963753A1 (en) 2016-05-19
WO2016075440A1 (en) 2016-05-19
AU2015344858B2 (en) 2020-08-20
US20180196050A1 (en) 2018-07-12
CA2963753C (en) 2022-10-18
ES2705614T3 (es) 2019-03-26
JP6808632B2 (ja) 2021-01-06
GB201419976D0 (en) 2014-12-24
EP3218720B1 (en) 2019-01-02
US10634678B2 (en) 2020-04-28
NZ729773A (en) 2020-02-28
MX2017006075A (es) 2017-10-24
AU2015344858A1 (en) 2017-03-30
EP3218720A1 (en) 2017-09-20
BR112017006315A2 (pt) 2018-01-16
BR112017006315B1 (pt) 2024-01-23
DK3218720T3 (en) 2019-02-11
JP2017537148A (ja) 2017-12-14
US20200018756A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
GB2530312B (en) Data compression
GB2530311B (en) Data compression
GB201401603D0 (en) Biomarkers
GB201420908D0 (en) Biomarkers
HK1231555A1 (zh) 生物標誌物及其用途
SI3218720T1 (sl) Biomarkerji za napredovanje bolezni pri melanomu
GB201404189D0 (en) Novel biomarkers
SG11201608244TA (en) Biomarkers for assessing hiv
GB201421961D0 (en) Capnometer
GB2546911B (en) Pivot block
GB201416015D0 (en) Biomarker
GB2543977B (en) Cushion Pin
GB201512133D0 (en) Biomarkers
GB201414686D0 (en) Fame determination
GB201419494D0 (en) Variations
GB201420239D0 (en) Biomarker
GB2530503B (en) Pin
GB201519704D0 (en) Biomarkers
GB201521446D0 (en) Biomarker
GB201513683D0 (en) Biomarkers
GB201411343D0 (en) Biomarker
GB201409793D0 (en) Biomarker
GB201503068D0 (en) ToPo
GB201403564D0 (en) Biomarker
GB201402166D0 (en) Biomarker